Guselkumab (Tremfya) Should NOT Be Used in Organ Transplant Patients
Guselkumab is contraindicated or should be avoided in organ transplant recipients due to the risk of serious infections and complications from additional immunosuppression in an already immunocompromised population. The FDA-approved guidelines explicitly state to "use caution in patients with pre-existing immunosuppression-related conditions" 1, and organ transplant recipients fall squarely into this high-risk category.
Why This Matters for Transplant Patients
Organ transplant recipients are maintained on chronic immunosuppressive therapy (typically tacrolimus-based regimens) to prevent graft rejection 2. Adding guselkumab—an IL-23 inhibitor that further suppresses immune function—creates a dangerous compounding effect:
Infection Risk: Guselkumab may increase the risk of infections 3. The FDA label specifically warns not to initiate treatment in patients with clinically important active infections 3. Transplant patients already face elevated infection risks, including CMV, bacterial infections, and opportunistic pathogens 4.
Immunosuppression Layering: The guideline explicitly advises caution in pre-existing immunosuppression 1. Transplant patients on tacrolimus, mycophenolate, or other agents are already profoundly immunosuppressed—adding guselkumab would intensify this state unpredictably.
No Safety Data: There are no published studies evaluating guselkumab safety in transplant recipients. All major trials excluded immunocompromised patients 5.
Clinical Algorithm for Decision-Making
If a transplant patient presents with psoriasis or psoriatic arthritis:
- First-line: Use topical therapies, phototherapy, or conventional systemic agents (methotrexate, cyclosporine) that have established safety profiles in transplant populations
- If biologics are necessary: Consider agents with more transplant-specific data or consult transplant nephrology/hepatology before initiating any biologic
- Absolute avoidance: Do not use guselkumab without compelling evidence of safety in this population
Key Safety Concerns from FDA Labeling
The FDA label warns 3:
- Serious hypersensitivity reactions including anaphylaxis may occur
- Evaluate for tuberculosis prior to treatment
- Avoid live vaccines during treatment
- Monitor for infections and discontinue if serious infection develops
These warnings are particularly concerning in transplant recipients who:
- Already require TB screening and prophylaxis
- Cannot receive live vaccines
- Have baseline infection susceptibility from maintenance immunosuppression
- May develop atypical or severe infections more readily
Common Pitfall to Avoid
Do not assume that because guselkumab has a "favorable safety profile" in general populations 6, 7, 8 that it is safe in transplant patients. All published real-world and clinical trial data excluded immunocompromised individuals. The 94% drug survival rate at 93 weeks 8 and excellent safety in TNF-experienced patients 9 apply only to immunocompetent psoriasis patients, not those on chronic transplant immunosuppression.
The risk-benefit calculation fundamentally changes when baseline immune function is already compromised. Prioritizing graft survival and preventing life-threatening infections must take precedence over treating psoriasis in this population.